Education
About Us
Working with TipRanks
Follow Us
Artiva Biotherapeutics, Inc. (ARTV)
:ARTV
RESEARCH TOOLSreports
ARTV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.29 - $17.31
Previous CloseN/A
Volume23.16K
Average Volume (3M)116.46K
Market Cap
$59.45M
Enterprise Value$73.79M
Total Cash (Recent Filing)$40.23M
Total Debt (Recent Filing)$14.35M
Price to Earnings (P/E)―
Beta1.07
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.94
Shares Outstanding24,363,120
10 Day Avg. Volume89,220
30 Day Avg. Volume116,464
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)229.97
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit293.97
Enterprise Value/Ebitda-1.14
Forecast
1Y Price Target
$20.25Price Target Upside729.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Artiva Biotherapeutics, Inc. News
PremiumCompany Announcements
Artiva Biotherapeutics Reports 2024 Financial Results
PremiumCompany Announcements
Artiva Biotherapeutics Reports Q3 2024 Financial Results---
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyArtiva reported impressive data of AlloNK + rituximab with a 62% complete response rate in CAR-T naive patients with aggressive NHL.
Manufacturing And Cost EfficiencyThe company’s manufacturing process facilitates low costs, consistent products, and scalability, allowing production of AlloNK for an estimated COGS of less than $6,000 per patient.
Regulatory DesignationAlloNK has received FDA Fast Track designation for the treatment of lupus nephritis in combination with Rituxan or Gazyva.
Bears Say
Development PlansArtiva does not currently plan to continue development for AlloNK + rituximab in NHL.
Strategic FocusThe company is not pursuing oncology at this time due to costs and commercial considerations.
---
ARTV FAQ
What was Artiva Biotherapeutics, Inc.’s price range in the past 12 months?
Artiva Biotherapeutics, Inc. lowest stock price was $2.29 and its highest was $17.31 in the past 12 months.
What is Artiva Biotherapeutics, Inc.’s market cap?
Artiva Biotherapeutics, Inc.’s market cap is $59.45M.
When is Artiva Biotherapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Artiva Biotherapeutics, Inc.’s earnings last quarter?
Artiva Biotherapeutics, Inc. released its earnings results on Nov 12, 2024. The company reported -$0.92 earnings per share for the quarter, missing the consensus estimate of -$0.835 by -$0.085.
Is Artiva Biotherapeutics, Inc. overvalued?
According to Wall Street analysts Artiva Biotherapeutics, Inc.’s price is currently Undervalued.
Does Artiva Biotherapeutics, Inc. pay dividends?
Artiva Biotherapeutics, Inc. does not currently pay dividends.
What is Artiva Biotherapeutics, Inc.’s EPS estimate?
Artiva Biotherapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Artiva Biotherapeutics, Inc. have?
Artiva Biotherapeutics, Inc. has 24,363,120 shares outstanding.
What happened to Artiva Biotherapeutics, Inc.’s price movement after its last earnings report?
Artiva Biotherapeutics, Inc. reported an EPS of -$0.92 in its last earnings report, missing expectations of -$0.835. Following the earnings report the stock price went up 2.046%.
Which hedge fund is a major shareholder of Artiva Biotherapeutics, Inc.?
Currently, no hedge funds are holding shares in ARTV
---
Artiva Biotherapeutics, Inc. Stock Smart Score
Company Description
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
---
ARTV Stock 12 Month Forecast
Average Price Target
$20.25
▲(729.92% Upside)
Technical Analysis
Gilead Sciences
―
Fate Therapeutics
―
Iovance Biotherapeutics
―
Adaptimmune Therapeutics
―
Nkarta
―
Best Analysts Covering ARTV
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-54.90%
reiterated a buy rating 13 days ago
Copying Edward White's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -54.90% per trade.
---